Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > December 16, 2024
Daily News
December 16, 2024
- Takeda Sees Up to US$20 Billion Sales Potential with 6 Late-Stage Assets
December 16, 2024
- Teijin Seek Japan Approval for Ascendis’ Hypoparathyroidism Drug
December 16, 2024
- Amgen Japan Marks “Significant Milestone” with Tepezza Release, Eyes More Launches
December 16, 2024
- BMS Files Augtyro for NTRK-Positive Solid Tumors in Japan
December 16, 2024
- EA Pharma Bags Japan, Asia Rights to Newron’s Schizophrenia Drug
December 16, 2024
- Japan Citizens’ Group Opposes RWD-Only Drug Submissions
December 16, 2024
- LDP’s Tamura Renews Question over Product Coverage of Off-Year Revisions
December 16, 2024
- Mitsubishi Tanabe to Reinstate CEO Role, with Tsujimura at Its Helm
December 16, 2024
- BrightPath/Cellistic Pair Up for PI Trial of iPSC-derived NKT Cell
December 16, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…